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Abstract
miRNAs are an important class of small non-coding RNAs, which play a versatile role in
gene regulation at the post-transcriptional level. Expression of miRNAs is often deregulated
in human cancers. We analyzed small RNA massive parallel sequencing data from 50
locally advanced breast cancers aiming to identify novel breast cancer related miRNAs. We
successfully predicted 10 novel miRNAs, out of which 2 (hsa-miR-nov3 and hsa-miR-nov7)
were recurrent. Applying high sensitivity qPCR, we detected these two microRNAs in 206
and 214 out of 223 patients in the study from which the initial cohort of 50 samples were
drawn. We found hsa-miR-nov3 and hsa-miR-nov7 both to be overexpressed in tumor ver-
sus normal breast tissue in a separate set of 13 patients (p = 0.009 and p = 0.016, respec-
tively) from whom both tumor tissue and normal tissue were available. We observed hsa-
miR-nov3 to be expressed at higher levels in ER-positive compared to ER-negative tumors
(p = 0.037). Further stratifications revealed particularly low levels in the her2-like and basal-
like cancers compared to other subtypes (p = 0.009 and 0.040, respectively). We predicted
target genes for the 2 microRNAs and identified inversely correlated genes in mRNA
expression array data available from 203 out of the 223 patients. Applying the KEGG and
GO annotations to target genes revealed pathways essential to cell development, communi-
cation and homeostasis. Although a weak association between high expression levels of
hsa-miR-nov7 and poor survival was observed, this did not reach statistical significance.
hsa-miR-nov3 expression levels had no impact on patient survival.
Introduction
miRNAs are an important class of small non-coding RNAs, playing a versatile role in the gene
regulation at the post–transcriptional level [1–5]. These molecules have proven to be involved
in vital cellular functions, such as development, differentiation and metabolism [6–8]. In
recent years there has been increased focus on the role of miRNAs in cancer [9], and the
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implementation of next generation sequencing (NGS) has led to the identification of multiple
novel miRNAs as well as linked individual miRNA expression and combined signatures to
tumor characteristics [10]. Currently there are 2656 distinct human miRNAs identified in the
miRbase v22 [11], including more than 700 found to be deregulated in cancers [12].
Breast cancer is the most common malignancy in women. While outcome has improved
significantly over the last three decades, resistance to therapy still presents a major challenge
causing breast cancer related deaths [13]. As for chemoresistance in general, the underlying
biological mechanisms remain poorly understood [14].
Merging evidence has indicated miRNA deregulation to play a role in breast cancer biology
and outcome. Dysregulation of miRNAs may affect signal transduction pathways by targeting
oncogenes and tumor suppressor genes [15], important to cancer development, progression,
metastasis and potentially therapy response [16, 17]. Thus, while miR-10b, miR-125b, and
miR-145 are generally downregulated, other miRNAs, like miR-21 and miR-155, are generally
upregulated in breast cancer as compared to normal breast tissue [18]. Further, several miR-
NAs have revealed strong associations to clinical parameters [19, 20]: For example, differential
expression of miR-210, miR-21, miR-106b�, miR-197, miR-let-7i, and miR-210, have been
identified as a signature with prognostic value and also linked to invasiveness [21]. Moreover,
miR-21 has been found linked to breast cancer metastasis and poor survival [22], while mir-
29a overexpression has been shown to reduce the growth rate of breast cancer cells [23]. Given
that many of the observed miRNA alterations are strongly cancer specific, this has inspired
investigations into the potential use of miRNA as diagnostic biomarkers. Since miRNA are rel-
atively stable molecules, they may be particularly attractive biomarkers to screen for in liquid
biopsies (for original references, see [24])
miRNAs are also known to be differentially regulated across different subclasses of breast
cancer. E.g. while members of the mir-181 family are up regulated in breast cancer in general,
miR-181c in particular is activated by the expression of HER2 gene [25]. Also, miR-140 has
been found suppressed by estrogen stimulation in ERα-positive breast cancer cells, most likely
due to ER response elements in the flanking element of the miR-140 promoter [26].
In the present study, we analyzed global miRNA expression in 50 locally advanced breast
cancers using NGS, aiming to identify novel, potentially breast cancer specific miRNAs. We
identified and validated two novel miRNAs (one not previously described and one not previ-
ously reported in breast cancer), and subsequently evaluated their expression in an extended
patient series (n = 223), by high sensitivity qPCR. Both were found over-expressed in breast
cancer as compared to normal breast tissue. Considering different breast cancer subtypes, hsa-
miR-nov3 was expressed at particular high levels in ER-positive tumors contrasting lower levels
in basal-like and Her2-like tumors. No similar patterns were observed for hsa-miR-nov7.
Materials and methods
Patients
In the present work we have analyzed biopsy material from two breast cancer studies.
1) In the first study, incisional biopsies were collected before chemotherapy from 223
patients with locally advanced breast cancer in a prospective study designed to identify the
response to epirubicin (n = 109) and paclitaxel (n = 114) monotherapy. Primary response to
therapy as well as long-term follow up (>10 years or death) was recorded for all patients. This
cohort has been described in detail previously [27].
2) In the second study, tumor breast tissue and normal breast tissue from tumor bearing
and non-tumor bearing quadrants were collected from 46 anonymous breast cancer patients
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undergoing mastectomy, with the purpose of determining tissue estrogens. This cohort is
described in detail in [28].
Using NGS, we analyzed miRNA expression in 50 patients from study 1). Next, candidate
miRNAs were quantified using qPCR in all 223 patients from study 1), as well as 13 randomly
selected patients from study 2), where RNA was available from tumor tissue and matching
normal breast tissue (7 ER-positive and 6 ER-negative tumors). In addition, mRNA expression
array data was available for 203 out of the 223 patients in study 1).
All patients provided written informed consent, and the studies conducted in accordance
to national laws, regulation and ethical permissions (Norwegian health region West; REK
Vest).
Tissue sampling and RNA extraction
Tissue samples were snap-frozen in liquid nitrogen in the operating theatre and stored in liq-
uid nitrogen until further processing. Total RNA was extracted from the biopsies using miRva-
naTM kit (ThermoFisher), according to the manufacturer’s instructions. RNA integrity and
concentration were determined using Bioanalyzer 2000 and Nanodrop ND2000 spectropho-
tometer, respectively.
miRNA-sequencing
Sample preparation and single-end sequencing were performed at the core facility of the Nor-
wegian Genomics Consortium in Oslo, on Illumina HiSeq 2500, 1x50bp. De-multiplexing was
performed using the Illumina CASAVA software. FastQC was run on all samples with the
main purpose to assess sequence quality. The raw data are available through the Gene Expres-
sion Omnibus (accession: GSE145151).
Novel miRNA prediction
The raw sequencing files (fastq) were processed using the novel miRNA prediction algorithm
mirdeep v2.0.0.5 [10]. Potential novel miRNAs were identified using the human reference
genome (hg19) and already identified miRNAs from humans and other hominids from miR-
base 20 [29]. In the mirdeep2 algorithm, filtering parameters randfold P-value less than 0.05
and scores greater than or equal to 10 were applied. Precursor structures obtained after filter-
ing were manually identified based on the presence of 1–2 mismatches in the stem region, a
loop sequence of 4–8 nt, and the presence of mature sequence in the stem region (See S1 File.)
[30].
Validation of predicted novel miRNAs
Validation of the predicted novel miRNAs was performed by qPCR-based amplification of the
miRNAs, with subsequent cloning and capillary sequencing of the products, to pinpoint the
exact size and sequence of the miRNAs (see sections below for details).
cDNA synthesis and qPCR
cDNA from miRNAs was prepared using Exiqon’s Universal cDNA synthesis kit II, with 20 ng
of total RNA as input. qPCR was performed using Exiqon’s miRCURY LNA™ Universal RT
microRNA PCR system, with custom Pick-&-Mix ready to use PCR plates with an inter-plate
calibrator, on a LightCycler 480 instrument (Roche). Relative expression levels for each sample
were calculated by dividing the expression of the gene of interest on the average expression of
two reference miRNAs: miR-16-5p and miR-30b-5p.
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miRNA cloning and capillary sequencing
End products from custom miRNA specific qPCR were cloned into pCR 2.1 TOPO-TA vector
(Life Technologies) by TOPO-TA cloning according to the manufacturer’s instructions. The
generated plasmids were amplified by transformation and cultivation of E. coli TOP10 cells
(Life Technologies). The plasmids were then isolated using the Qiagen miniprep kit according
to the manufacturer’s instructions.
Sequencing was performed using the BigDye v.1.3 system (Applied Biosystems) and the
primers following thermocycling conditions as previously described [31]. Capillary electro-
phoresis and data collection were performed on an automated capillary sequencer (ABI3700).
Target prediction and pathway analysis
Target prediction was performed using the offline algorithm miRanda [32, 33] and the online
algorithms miRDB [34] and TargetScanHuman Custom (Release 5.2) [35].
miRanda predicts gene targets based on position specific sequence complementarity
between miRNA and mRNA using weighted dynamic programming, an extension of the
Smith-Waterman algorithm [36]. Also, the miRanda algorithm uses the free energy estimation
between duplex of miRNA: mRNA (Vienna algorithm [37]) as an additional filter.
The miRDB is an online database of animal miRNA targets, which uses SVM (Support Vec-
tor Machine) machine-learning algorithm trained with miRNA-target binding data from
already known and validated miRNA-mRNA interactions [34, 38].
TargetScanHuman Custom predicts biological miRNA targets by searching for match for
the seed region of the given miRNA that is present in the conserved 8-mer and 7-mer sites
[35]. It also identifies sites with conserved 3’ pairing from the mismatches in the seed region
[39, 40].
An in-house pan-cancer panel of 283 tumor suppressor genes was used to filter target genes
of interest. The panel was generated based on the tumor suppressors within the CGPv2/3-pan-
els [41], Roche’s Comprehensive Cancer Design as well as a manual literature search (S1
Table).
Further, we used GATHER, a functional gene enrichment tool, which integrates various
available biological databases to find functional molecular patterns, in order to find biological
context from the target gene list [42]. With the help of GATHER, we did KEGG pathway [43],
and GO (gene ontology) enrichment analyses for the common genes predicted by all three pre-
diction algorithms. Further, validations were performed using DAVID [44] and topGO [45].
mRNA expression
In the interest of validating miRNA targets, we analyzed inverse correlations between miRNA
expression and mRNA levels. mRNA expression levels were extracted from microarray analy-
ses performed on a Human HT-12-v4 BeadChip (Illumina) after labeling (Ambion; Aros
Applied Biotechnology). Illumina BeadArray Reader (Illumina) and the Bead Scan Software
(Illumina) were used to scan BeadChips. Expression signals from the beads were normalized
and further processed as previously described [46]. We re-annotated the data set using illumi-
naHumanv4.db from AnnotationDbi package, built under Bioconductor 3.3 in R [47], to select
only probes with “Perfect” annotation[48]. The probes represented 21043 identified and
unique genes (13340 represented by single probe and 7703 represented by multiple probes). In
the cases of multiple probes targeting the same gene, we calculated fold difference for these
probes. This was done to avoid losing potentially relevant biological information if expression
of one probe was significantly higher that expression of another. However, for no genes did we
find a fold difference >2 fold. Therefore, the mean expression for each such gene, was
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calculated based on the values form each probe, weighted according to the number of beads
per probe.
Statistics
Expression levels of miRNAs in tumor versus normal tissue were compared by Wilcoxon rank
tests for paired samples. Inverse correlations between miRNA expression and mRNA expres-
sion were assessed by Spearman tests. The potential impact of the novel miRNAs on long-term
outcome (relapse-free survival and disease-specific survival) in breast cancer patients was cal-
culated by Log-rank tests and illustrated by Kaplan-Meier curves, using the SPSS software
v.19. All p-values are reported as two-sided.
Results
Novel miRNA prediction
In order to identify novel miRNAs, 50 patients with locally advanced breast cancer (from
study 1, see materials and methods) were subject to global miRNA-sequencing using massive
parallel sequencing. On average, the dataset resulted in 3 million reads per sample. Using the
miRNA identifier module in miRDeep2, we detected 10 novel miRNAs (Table 1). Eight out of
these 10 miRNAs were detected in a single sample only, while two were expressed in two or
more patients and therefore regarded as the most reliable predictions. These two miRNAs,
here temporarily named hsa-miR-nov3 and hsa-miR-nov7, were found in tumor samples from
2 and from 6 patients, respectively. For both of these novel miRNAs, we identified precursor
structures with not more than one or two mismatches in the stem region, as well as the pres-
ence of mature miRNA sequences (Fig 1; S1 Fig). Therefore, we selected these two miRNAs for
further analyses. Cross-checking the miRCarta database [49], no hits were found for either of
the two, but notably, while this work was conducted, hsa-miR-nov7 was identified by another
team in lymphomas, and reported as miR-10393-3p [50].
In-vitro validation of novel micro RNAs
Next, we aimed to validate our in-silico predictions and confirm that the sequences from
which we identified hsa-miR-nov3 and hsa-miR-nov7 represented bona-fide novel miRNAs
expressed in the patients. Utilizing total RNA from the patients found to express the two pre-
dicted novel miRNAs, we performed global poly-adenylation and cDNA synthesis followed by
miRNA-specific qPCR amplification. For both miRNAs we observed positive qPCR reactions.
Further, end products of the qPCRs were then ligated into carrier-plasmids and sequenced.
Table 1. Novel miRNA sequences as predicted by mirdeep v2.0.0.5 from massive parallel sequencing of total miRNA in 50 locally advanced breast cancers.
miRNA Co-ordinate Mature sequence Strand Number of samples
hsa-miR-nov2 chr2:36662749..36662809 AAAAACTGCGATTACTTTTGCA - 1
hsa-miR-nov3 chr3:186505088..186505149 AAAGCAGGATTCAGACTACAATAT + 2
hsa-miR-nov3_2 chr3:132393169..132393224 CAAAAACTGCAATTACTTTTGC + 1
hsa-miR-nov4 chr4:155140075..155140134 AAAAGTAATCGCTGTTTTTG + 1
hsa-miR-nov7 chr7:138728845..138728903 AATTACAGATTGTCTCAGAGA - 6
hsa-miR-nov8 chr8:116546693..116546762 TTAGAGCTTCAACCTCCAGTGTGA - 1
hsa-miR-nov10 chr10:31840034..31840078 CGCGGGTGCTTACTGACCCT + 1
hsa-miR-nov10_2 chr10:72163928..72163994 GCGGCGGCGGCGGCGGCG + 1
hsa-miR-nov17 chr17:36760852..36760906 CCCAGCCCCACGCGTCCCCATG - 1
hsa-miR-nov20 chr20:26189318..26189366 TGGCCGAGCGCGGCTCGTCGCC - 1
https://doi.org/10.1371/journal.pone.0225357.t001
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We confirmed the resulting plasmids to contain the predicted miRNA sequences. Further, in
both cases, the sequences were flanked by a poly A tail, confirming that the original molecules
used as input in the poly-adenylation were present as short 22nt RNAs (Fig 2). Thus, we con-
firmed the presence of miRNAs with the exact sequence as predicted from the NGS-based
data.
Overexpression of hsa-miR-nov7 and hsa-miR-nov3 in breast cancer
Given that the sensitivity for the novel miRNAs was better in the qPCR than in the miRNA
massive parallel sequencing (MPS) analysis, we aimed to assess whether the miRNAs were
expressed in a limited number of breast cancer patients only (as indicated by their detection in
2 and 6 out of 50 patients in the MPS analysis), or if they were detectable in a higher fraction of
patients, when applying a more sensitive detection method. We therefore performed qPCR to
quantify the expression levels of hsa-miR-nov7 and hsa-miR-nov3 in tumor tissue across the
entire cohort of patients from study 1 (n = 223). With this method, we detected hsa-miR-nov7
and hsa-miR-nov3 in 206 and 214 samples out of total 223 samples respectively, albeit at vari-
able levels (Fig 3).
Interestingly, while no difference in the expression levels of hsa-miR-nov7 was observed
between breast cancer subgroups, we found a significant difference in the expression levels of
has-miR-nov3 related to estrogen receptor status. Thus, the expression levels of has-miR-nov3
were higher in ER-positive as compared to ER-negative tumors (p = 0.037; Fig 4A). Further,
Fig 1. Predicted novel miRNAs. Depiction of novel miRNAs (A) hsa-miR-nov3 and (B) hsa-miR-nov7, identified by
miRDeep2, showing (i) predicted mature and star sequences, exp, probabilistic model expected from Drosha/Dicer
processing and obs, observed sequences from sequencing data (ii) density plot for read counts for mature and star
sequences as well as (iii) miRNA secondary structure.
https://doi.org/10.1371/journal.pone.0225357.g001
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assessing the expression levels of the two miRNAs in mRNA-based subclasses of breast cancer
according to the Perou classification [51], comparing all five classes, we observed a significant dif-
ference between the subtypes with respect to miR-nov3 expression (p = 0.041; Kruskal-Wallis test;
Fig 4C). We found hsa-miR-nov3 levels to be lower in HER2 like (p = 0.009; Mann-Whitney test)
and basal-like (p = 0.04; Mann-Whitney) tumors as compared to tumors of the other classes.
Following the finding that the two miRNAs were detectable in more than 90 percent of
patients, in order to assess whether the expression of these miRNAs were tumor specific we
compared the levels of hsa-miR-nov7 and hsa-miR-nov3 expression in breast cancer tissue ver-
sus normal breast tissue. For this purpose, we randomly selected 13 patients from a study
where samples of breast tumor tissue and matching normal tissue from a non-tumor bearing
quadrant of the same breast were available (study 2, see materials and methods) [28]. We
detected expression of the novel miRNAs in both tumor- and normal tissue samples for all 13
patients. Notably, we found hsa-miR-nov3 expression to be elevated in tumor compared to
normal tissue in 10 out of the 13 patients (p = 0.009; Wilcoxon test; Fig 5A). Similar findings
Fig 2. miRNA sequences. Chromatogram of capillary-sequenced qPCR products after hsa-miR-nov3 (A) and hsa-miR-nov7 (B) amplification.
Highlighted background indicates the 22nt miRNA-sequence region (reverse complementary), followed by the Adenine homopolymer
indicating in vitro adenylation at the expected site, confirming the exact size and sequence of the predicted miRNAs.
https://doi.org/10.1371/journal.pone.0225357.g002
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were observed for hsa-miR-nov7 with elevated expression in 10 out of 13 tumors (Wilcoxon:
p = 0.016; Fig 5B). The level of overexpression (i.e. the ratio of expression levels in tumor ver-
sus normal tissue) for the two miRNAs did not correlate to each other (p>0.2; Spearman).
Notably, overexpression of hsa-miR-nov7 in tumor versus normal tissue was observed pre-
dominantly in ER-positive tumors (overexpression in 7 out of 7 ER-positive tumors, contrast-
ing 3 out of 6 ER-negative tumors; p = 0.070; Fischer exact test).
hsa-miR-nov7 and hsa-miR-nov3 target prediction
Based on our finding of both novel miRNAs to be overexpressed in breast cancer, we next
aimed to elucidate the functional roles for hsa-miR-nov7 and hsa-miR-nov3 by identifying
Fig 3. Expression of novel miRNAs in breast cancer tissue. Bars indicate the relative expression of hsa-miR-nov3 (A)
and hsa-miR-nov7 (B) in 223 breast cancer patients.
https://doi.org/10.1371/journal.pone.0225357.g003
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potential targets. We performed in silico target predictions using three different algorithms–
miRanda, miRDB and TargetScan Human Custom. miRanda, which predicts possible targets
from human transcripts in general, predicted 9200 and 12315 target genes for hsa-miR-nov7
and hsa-miR-nov3, respectively. miRDB, which contains curated and possible miRNA targets,
predicted 570 and 530 target genes each for hsa-miR-nov7 and hsa-miR-nov3, respectively,
while TargetScanHuman custom predicted 633 target genes for hsa-miR-nov7, and 282 target
genes for hsa-miR-nov3. For increased stringency in our predictions, we restricted the poten-
tial targets to the ones called by all three algorithms (Fig 6). This left a total of 97 and 180
potential targets for hsa-miR-nov3 and hsa-mir-nov7, respectively.
The two lists of 97 and 180 predicted gene targets were then used for KEGG pathway analy-
sis and GO enrichment analysis using GATHER. The top 10 KEGG pathways and GO terms
for each microRNAs are listed in Table 2. The KEGG and GO annotations for hsa-miR-nov3
showed pathways that are important in cell development, communication and cytoskeletal
organization. Similar analysis for hsa-miR-nov7 unveiled pathways playing a vital role in cell
functions such as communication and homeostasis. These findings were largely validated by
performing the same analyses applying alternative tools (DAVID and topGO; S2 Table).
Fig 4. Expression of novel miRNAs in breast cancer tissue. Expression levels stratified by ER-status (A, B) and by expression subtypes (C,
D).
https://doi.org/10.1371/journal.pone.0225357.g004
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Thus, both these miRNAs implied cell functions that are vital to cancer development and
progression.
In order to further substantiate these in-silico predictions, we performed a complete Spear-
man correlation analysis between the expression levels of hsa-miR-nov7 and hsa-miR-nov3 and
mRNA expression array data available for 203 out of the 233 patients in study 1. Assuming the
miRNAs, in general, to execute their function by suppressing gene expression (mRNA degra-
dation), we restricted the analysis to genes which were negatively correlated to expression of
the miRNAs. The top ranking negatively correlated genes are listed in Table 3. Notably, the
only genes with Rho-values < -0.2 were RMND5A for hsa-miR-nov3 and GLUD1 and SASH1
for hsa-miR-nov7. Given that the two novel miRNAs were overexpressed in breast cancer tis-
sue, we went on to restrict the correlation analysis to an in-house list of 283-tumor suppressor
Fig 5. Expression of novel miRNAs in breast cancer tissue. Bars indicate the ratio of expression in tumour tissue vs.
matched normal breast tissue in 13 breast cancer patients, for hsa-miR-nov3 (A) and hsa-miR-nov7 (B).
https://doi.org/10.1371/journal.pone.0225357.g005
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Fig 6. Target genes predicted. Venn-diagrams illustrating the number of target genes predicted by TargetScan,
mirDB and Miranda for the two novel miRNAs hsa-mir-nov3 (A) and hsa-mir-nov7 (B).
https://doi.org/10.1371/journal.pone.0225357.g006
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Table 2. Top 10 (arbitrary cut-off) GO and KEGG annotation.
A) GO annotation—hsa-miR-nov3
# Annotation ln(Bayes factor)a neg ln(p value)b FE: neg ln
(p value)c
FE: neg ln(FDR)d
1 GO:0009653 [3]: morphogenesis 94.88 7.98 100.5 92.91
2 GO:0007275 [2]: development 87.32 7.58 92.89 85.99
3 GO:0007154 [3]: cell
communication
85.41 7.46 90.99 84.5
4 GO:0009887 [4]: organogenesis 74.65 6.99 80.24 74.26
5 GO:0048513 [3]: organ
development
74.65 6.99 80.24 74.26
6 GO:0007165 [4]: signal
transduction
74.2 6.97 79.77 73.97
7 GO:0007242 [5]: intracellular
signaling cascade
66.52 6.59 72.18 66.53
8 GO:0007010 [6]: cytoskeleton
organization and biogenesis
55.54 6.04 61.15 55.63
9 GO:0009790 [3]: embryonic
development
48.63 5.7 54.28 48.88
10 GO:0006928 [4]: cell motility 47.82 5.65 53.49 48.2
B) KEGG annotation—hsa-miR-nov3
# Annotation Total Genes With Ann ln(Bayes factor)a neg ln(p value)b FE: neg ln
(p value)c
FE: neg ln(FDR)d
1 path:hsa04810: Regulation of actin
cytoskeleton
35 9.03 4.07 13.96 9.57
2 path:hsa04010: MAPK signaling
pathway
36 6.93 3.75 11.8 8.1
3 path:hsa04510: Focal adhesion 32 4.15 3.26 8.94 5.94
4 path:hsa04110: Cell cycle 18 4.1 3.25 9.08 5.95
5 path:hsa04060: Cytokine-cytokine
receptor interaction
33 3.23 3.07 7.97 5.24
6 path:hsa04620: Toll-like receptor
signaling pathway
17 2.97 3.01 7.92 5.24
7 path:hsa04210: Apoptosis 16 2.13 2.82 7.06 4.55
8 path:hsa04512: ECM-receptor
interaction
14 1.17 2.55 6.09 3.72
9 path:hsa04630: Jak-STAT
signaling pathway




5 0.7 2.41 5.9 3.59
C) GO annotation—hsa-miR-nov7





60.17 6.3 65.79 58.14
2 GO:0007275 [2]:
development
54.83 6 60.38 53.43
3 GO:0007165 [4]:
signal transduction
50.84 5.81 56.44 49.89
4 GO:0009653 [3]:
morphogenesis
48.96 5.72 54.56 48.3
(Continued)
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41.31 5.3 46.94 40.9
6 GO:0009987 [2]:
cellular process
40.56 5.26 46.33 40.48
7 GO:0009887 [4]:
organogenesis
40.37 5.25 45.94 40.24
8 GO:0048513 [3]:
organ development








39.18 5.18 44.62 39.27
D) KEGG annotation—hsa-miR-nov7














33 3.15 3.04 7.94 4.57
4 path:hsa04210:
Apoptosis













3 1.12 2.54 6.48 3.7
8 path:hsa04510:
Focal adhesion









13 -0.28 0 4.61 2.39
a Measure of the strength of annotation
b p-value for the Bayes factor estimate
c p-value for Fishcer’s exact test
d FDR for Fishcer’s exact test
https://doi.org/10.1371/journal.pone.0225357.t002
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Table 3. Spearman correlation table for hsa-miR-nov3 and hsa-miR-nov7 and their top 25 target genes (arbitrary cut-off for inclusion in the table; ranked by inverse
correlation).
A) hsa-miR-nov3
Gene Symbol Estimate P.value Expression (mean)
RMND5A -0.2018 0.0038 14.0750
YES1 -0.1649 0.0184 17.0218
PALM2-AKAP2 -0.1455 0.0378 13.0997
SLC7A1 -0.1224 0.0811 16.8650
RAPGEF5 -0.1208 0.0853 14.9652
CTDSPL2 -0.1196 0.0885 15.4945
SLC4A5 -0.1077 0.1251 15.0101
HIPK1 -0.1046 0.1366 13.3737
ABHD12 -0.0998 0.1555 16.2313
FMNL2 -0.0982 0.1624 16.0939
POU4F1 -0.0933 0.1844 13.4684
RPS6KA3 -0.0905 0.1981 14.6430
LARP1 -0.0890 0.2054 15.0210
WIPI2 -0.0702 0.3184 14.7316
MTCH1 -0.0575 0.4139 18.6604
DIAPH1 -0.0528 0.4530 16.7109
MARCKS -0.0481 0.4946 18.6286
LUZP1 -0.0453 0.5200 17.1097
DNAJC8 -0.0449 0.5238 18.2152
CLOCK -0.0436 0.5354 15.7894
SLAMF6 -0.0415 0.5557 15.4277
CDAN1 -0.0405 0.5655 16.6394
PCDH11X -0.0359 0.6104 13.4661
RYBP -0.0346 0.6234 16.9184
FGF1 -0.0344 0.6249 13.9423
B) hsa-miR-nov7
Gene Symbol Estimate P.value Expression (Mean)
GLUD1 -0.2274 0.0011 18.0399
SASH1 -0.2095 0.0026 16.9164
MARK1 -0.1883 0.0070 15.0356
ARID5B -0.1877 0.0072 17.7569
ELOVL5 -0.1854 0.0079 17.5656
PUM1 -0.1707 0.0147 17.8295
PNRC2 -0.1599 0.0224 15.4674
UNC13B -0.1583 0.0238 15.5633
FLRT2 -0.1581 0.0239 15.7323
ZFHX4 -0.1482 0.0344 14.7383
CHIC1 -0.1479 0.0348 13.5807
MAN1A1 -0.1457 0.0375 15.4956
CPEB2 -0.1387 0.0478 14.6995
PDE4D -0.1377 0.0495 13.9823
TMED7 -0.1366 0.0514 17.1083
NDFIP1 -0.1280 0.0680 16.1458
CSMD1 -0.1269 0.0704 13.8158
MITF -0.1187 0.0908 14.0482
(Continued)
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genes previously described. Among these tumor suppressors, we found 115 to be negatively
correlated to hsa-miR-nov7 and 119 to hsa-miR-nov3 (S3 Table). Assessing the intersection
between these negatively correlated tumor suppressor genes and the predicted targets, we
obtained a list of one gene for hsa-miR-nov3 (ATRX) and three genes for hsa-miR-nov7 (APC,
SFRP2 and CDH11), but the correlations were non-significant in all 4 cases (Table 4, Fig 7).
In order to get a broader overview of potential biological function, we selected the 100 gene
transcripts with the strongest positive and the top 100 gene transcripts with the strongest nega-
tive correlation to the two miRNAs (independent of previous target-predictions) and per-
formed gene ontology analyses. We detected no cancer related pathways or cellular functions
to be significantly associated with hsa-miR-nov7 (S4 Table). However, for hsa-miR-nov3,
KEGG analysis of the negatively correlated genes revealed associations to Hepatorcellular car-
cinoma as well as several pathways related to drug metabolism (S5 Table). Notably, when seek-
ing to validate these findings by application of alternative tools (DAVID and topGO) the latter
was not validated. (S6 and S7 Tables).
Expression of hsa-miR-nov7 and hsa-miR-nov3 and clinical outcome in
breast cancer
Since both hsa-miR-nov7 and hsa-miR-nov3 were overexpressed in the tumor tissue of breast
cancer patients, we assessed whether any of the two novel miRNAs were associated to clinical
outcomes in study 1 (223 breast cancer patients). Given that these patients were enrolled in a
prospective study specifically designed to assess response to primary chemotherapy adminis-
tered as epirubicin or paclitaxel monotherapy in a neoadjuvant setting [27, 52], we assessed
the association of hsa-miR-nov7 and hsa-miR-nov3 levels with primary therapy response and
with long term survival (10-years).
We found no association between any of the two novel miRNAs and primary response to
either epirubicin or paclitaxel (S8 Table). Regarding survival, we observed a weak association
between high levels of hsa-miR-nov7 and poor survival in the paclitaxel treated arm of the
study, with the strongest associations observed for relapse free survival, however, none of these
associations reached statistical significance (Fig 8). No effect was observed in the epirubicin
treated arm. Further, for hsa-miR-nov3, no significant correlation to outcome was recorded.
Table 3. (Continued)
ITSN1 -0.1185 0.0915 14.8011
CTDSPL2 -0.1178 0.0932 15.4945
ATAD2B -0.1178 0.0932 14.9892
SFRP2 -0.1129 0.1080 18.4511
DPP10 -0.1119 0.1110 13.4306
BMPR2 -0.1107 0.1149 17.1664
EIF5A2 -0.1100 0.1174 14.5450
https://doi.org/10.1371/journal.pone.0225357.t003
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Given the skewed expression levels between breast cancer subtypes for hsa-miR-nov3, we
performed survival analyses stratified for ER-status and subtypes. These analyses revealed no
significant associations to survival (Log rank test p-values ranging from 0.09 to 0.98).
Discussion
We investigated whether we could detect novel, previously undescribed miRNAs and, if so,
address their potential association to other defined biological parameters and to outcome in a
cohort of locally advanced breast cancer. We successfully predicted 10 new miRNAs, out of
which 2 were deemed reliable because of their detected presence in more than one patient.
Although these two novel miRNAs (preliminary termed hsa-miR-nov7 and hsa-miR-nov3)
were only predicted from 8 samples among the 50 initially sequenced biopsies, we found them
to be expressed in all patients by highly sensitive qPCR at varying levels. In addition to our in
vitro validations, the qPCR detection validated the initial NGS based analysis, detecting these
two miRNAs.
Since expression of the two miRNAs was confirmed in breast tumor tissue from the major-
ity of patients analyzed, we went on to assess the relative expression levels in tumor versus
matched normal breast tissue, collected from a non-tumor bearing quadrant. Our finding that
both novel miRNAs had higher expression levels in tumor than in normal tissue indicates a
potential functional role in breast cancer. However, although being overexpressed, the biologi-
cal role of these two miRNAs in cancer should be interpreted with caution. The expression
Fig 7. Correlations to tumor suppressor genes. Scatter plots showing correlation of target tumor suppressors with A)
hsa-miR-nov3 and B) hsa-miR-nov7.
https://doi.org/10.1371/journal.pone.0225357.g007
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levels are very low, and it is therefore uncertain whether they will have a major impact on cel-
lular functions. Notably, given our approach and identification of the two miRNAs with low
expression level, this indicates that there may currently be a limited potential for new discover-
ies of miRNAs high expression levels and strong functional roles in breast cancer. However,
when assessing the potential functional roles of these microRNAs by in silico prediction of tar-
gets followed by validation using correlation to mRNA-array data, the KEGG and GO annota-
tions for these targets revealed cellular functions of potential importance in development and
progression of cancer. As such, our present findings may warrant further investigations into
the functions of the two miRNAs. Notably, regarding hsa-miR-nov3, it was of particular inter-
est that this miRNA was significantly higher expressed in ER-positive as compared to ER-nega-
tive breast cancers. Accordingly, we found relatively high expression levels of hsa-miR-nov3 in
tumors of the luminal and normal-like subtypes, contrasting low expression levels in basal-like
and her2-like tumors [53, 54]. This finding may indicate a potential role for hsa-miR-nov3
restricted to ER-positive tumors.
Regarding potential specific targets, we narrowed these down by first assessing the intersect
of three different target prediction algorithms, and then the intersect of this result with a
Fig 8. miRNAs and breast cancer survival. Kaplan-Meier curves showing (i) disease-specific and (ii) relapse-free
survival of locally advanced breast cancer patients treated with epirubicin or paclitaxel monotherapy in the
neoadjuvant setting (study 1), with respect to expression levels of (A) hsa-miR-nov3 and (B) hsa-miR-nov7 on all
samples.
https://doi.org/10.1371/journal.pone.0225357.g008
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predefined list of tumor suppressors. Although none of the remaining genes after this filtering
had a statistically significant inverse correlation with the miRNAs, we identified some poten-
tially interesting connections: For hsa-miR-nov3, we propose ATRX as a target. This is a gene
in the SWI/SNF family, involved in chromatin remodelling, and it has previously been found
subject to loss of heterozygosity (LOH) in breast cancer [55]. Importantly, we recently reported
mutations in the SWI/SNF family genes to be enriched in relapsed breast cancer as compared
to primary cancers [56]. Thus, this supports the hypothesis of a breast cancer promoting func-
tion for hsa-miR-nov3. For hsa-miR-nov7, we propose APC, SFRP2, and CDH11 as potential
targets. Interestingly, the two former are involved in regulation of the Wnt-signalling pathway
[57–59] and both have previously been reported as targets for several miRNAs in breast cancer
[60–62]. Taken together, this may imply a role for hsa-miR-nov7 in Wnt signaling. Notably,
during our work with the present project, hsa-miR-nov7, was identified by Lim and colleagues
and coined miR-10393-3p [50]. They found this miRNA to target genes involved in chromatin
modifications associated with pathogenesis of Diffuse large B-cell lymphoma (DLBCL). While
this differs from our present finding, it may likely be explained by tissue specific effects of the
miRNA.
Regarding any predictive or prognostic role for the two investigated miRNAs, we found no
significant impact on survival. While we recorded a non-significant trend towards an associa-
tion between miRnov7 expression and overall survival in the paclitaxel arm, further studies on
larger patient cohorts are warranted to clarify this issue. Alternatively, the miRNAs could play
a role in tumorigenesis but not later tumor progression. As such, the observed overexpression
in tumor tissue compared to normal breast tissue may be a remaining signal from
tumorigenesis.
Whether cancer related overexpression of the two miRNAs described here is merely conse-
quences of other molecular mechanisms in cancer cells or whether the two miRNAs may be
involved in tumorigenesis, but not subsequent cancer progression, remains unknown.
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